Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study.

[1]  Shiyu Jiang,et al.  Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis. , 2020, Current problems in cancer.

[2]  D. Klimstra,et al.  Classification of neuroendocrine neoplasms of the digestive system , 2019 .

[3]  Jiayi Shen,et al.  Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database. , 2019, Annals of translational medicine.

[4]  R. Parra-Medina,et al.  Neuroendocrine neoplasms of gastrointestinal tract and secondary primary synchronous tumors: A systematic review of case reports. Casualty or causality? , 2019, PloS one.

[5]  M. McCabe,et al.  Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study , 2019, The Lancet. Oncology.

[6]  Geetanjali R. Kamath,et al.  Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study , 2019, Pancreas.

[7]  T. Gregersen,et al.  The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study , 2018, Neuroendocrinology.

[8]  A. Trama,et al.  Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study. , 2017, European journal of cancer.

[9]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[10]  H. Frick,et al.  Multiple primary tumours: challenges and approaches, a review , 2017, ESMO Open.

[11]  H. Sorbye,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents , 2017, Neuroendocrinology.

[12]  M. Kesavan,et al.  Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. , 2016, Cancer biotherapy & radiopharmaceuticals.

[13]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  S. Holm,et al.  Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours , 2015, Neuroendocrinology.

[15]  M. Kesavan,et al.  Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up , 2014, Neuroendocrinology.

[16]  Chun‐Chieh Wu,et al.  Second Cancers in Patients with Neuroendocrine Tumors , 2013, PloS one.

[17]  H. Biersack,et al.  Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2013, The Journal of Nuclear Medicine.

[18]  E. Papini,et al.  Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY , 2012, Journal of Endocrinological Investigation.

[19]  R. Damhuis,et al.  Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. , 2012, Endocrine-related cancer.

[20]  Hermann Brenner,et al.  Multiple tumours in survival estimates. , 2009, European journal of cancer.

[21]  Arnold Knijn,et al.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. , 2009, European journal of cancer.

[22]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[24]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[25]  Z. Tulassay,et al.  [Neuroendocrine tumors of the digestive system]. , 2002, Orvosi hetilap.

[26]  J. Palazzo,et al.  Risk of Second Cancers in Patients with Colorectal Carcinoids , 2002, Diseases of the colon and rectum.

[27]  A. Bilchik,et al.  Gastrointestinal carcinoid tumors and second primary malignancies , 2000, Journal of surgical oncology.

[28]  D. Finkelstein,et al.  Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. , 1999, Annals of surgery.

[29]  J. Rehfeld,et al.  The new biology of gastrointestinal hormones. , 1998, Physiological reviews.

[30]  J C Reubi,et al.  Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. , 1997, Cancer research.

[31]  M. Melbye,et al.  Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population‐based study , 1995, Cancer.

[32]  J. Gerstle,et al.  The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. , 1995, Journal of the American College of Surgeons.

[33]  C. Heldin,et al.  Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. , 1994, Anticancer research.

[34]  I. Modlin,et al.  Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. , 2015, Frontiers of hormone research.

[35]  N. J. Bush,et al.  Carcinoid Tumor , 2022 .

[36]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[37]  J. Reubi,et al.  High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. , 1999, The Journal of clinical endocrinology and metabolism.